ArticleEndocrinology, diabetes & metabolism2026
Alanine Aminotransferase Elevation at Diagnosis of Youth-Onset Type 2 Diabetes: Prevalence, Predictors, and One-Year Outcomes.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionMetabolic dysfunction-associated steatotic liver disease (MASLD) and Type 2 Diabetes (T2D) are components of insulin resistance, but the prevalence of MASLD at the diagnosis of youth-onset T2D is unknown. We aimed to describe the prevalence of alanine aminotransferase (ALT) elevation, a biomarker for MASLD, in youth-onset T2D at diagnosis and after one year and investigate factors associated with ALT elevation.
methodsA single-centre retrospective cohort study was conducted of patients (age ≤ 21 years) diagnosed with T2D between 1/1/2010 and 31/12/2021, with ALT available at diagnosis. ALT elevation was defined as being greater than 1.5 times the upper range of normal based on patient sex.
resultsIn the cohort (n = 438), 58% of patients had ALT elevation at T2D diagnosis. Hispanic patients had higher odds of ALT elevation than non-Hispanic Black patients (p < 0.001), and lower HbA1c at diagnosis was associated with higher odds of ALT elevation (p < 0.001). Among patients followed for one year (n = 141), the prevalence of ALT elevation decreased from 65% to 47%. ALT at diagnosis was not associated with a change in Haemoglobin A1C (HbA1c) from diagnosis to one year of follow-up, nor was HbA1c at diagnosis associated with a change in ALT.
conclusionsALT elevation is common at T2D diagnosis in youth. HbA1c is negatively associated with ALT elevation at diagnosis, but ALT and HbA1c at diagnosis did not impact the change in the corresponding marker at one year. The prevalence of elevated ALT varies between groups, and analysis of disease course within subpopulations is pertinent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.